

Attaphol Pawarode

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633454/publications.pdf>

Version: 2024-02-01

71
papers

2,079
citations

279701

23
h-index

243529

44
g-index

74
all docs

74
docs citations

74
times ranked

3564
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210
2	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	2.3	166
3	Natural History of Untreated Primary Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 386-391.	0.6	146
4	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	0.6	140
5	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
6	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology, The</i> , 2014, 15, 87-95.	5.1	113
7	Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. <i>Haematologica</i> , 2013, 98, 179-184.	1.7	84
8	±1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018, 131, 1372-1379.	0.6	81
9	Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 179-188.	1.1	75
10	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
11	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017, 123, 3141-3149.	2.0	65
12	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	2.5	63
13	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€cell lymphoma, nasal type: a <scp>CIBMTR</scp> analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	1.2	59
14	Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. <i>Blood</i> , 2017, 130, 1760-1767.	0.6	57
15	TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1525-1532.	2.0	50
16	Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 522-528.	2.0	49
17	Predictive Value of Bronchiolitis Obliterans Syndrome Stage Op in Chronic Graft-versus-Host Disease of the Lung. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1127-1131.	2.0	43
18	Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 862-868.	2.0	40

#	ARTICLE	IF	CITATIONS
19	FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. <i>Bone Marrow Transplantation</i> , 2016, 51, 511-520.	1.3	40
20	Outcomes of primary hepatocellular carcinoma treatment: An 8-year experience with 368 patients in Thailand. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 860-864.	1.4	35
21	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	2.5	35
22	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
23	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
24	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
25	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
26	Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1426-1434.	2.0	20
27	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
28	Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan \bar{A} -4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML. <i>Blood</i> , 2010, 116, 35-35.	0.6	16
29	Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. <i>Leukemia Research</i> , 2007, 31, 1589-1592.	0.4	15
30	Subcutaneous Panniculitis-Like T-Cell Lymphoma With Bone Marrow Involvement. <i>American Journal of Clinical Pathology</i> , 2015, 143, 265-273.	0.4	14
31	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
32	Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 155-160.	1.0	13
33	Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 338-341.	0.6	12
34	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 54-60.	2.0	12
35	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	2.5	12
36	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10

#	ARTICLE	IF	CITATIONS
37	Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Advances, 2021, 5, 5047-5056.	2.5	10
38	Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Annals of Hematology, 2015, 94, 1033-1041.	0.8	9
39	Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study. Radiology, 2016, 278, 449-457.	3.6	7
40	Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease. Blood, 2010, 116, 675-675.	0.6	6
41	Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1682-1688.	2.0	5
42	Mitigating Damage Response with CD24 Fusion Protein for Prevention of Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, S52-S53.	2.0	5
43	Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention. Blood, 2012, 120, 740-740.	0.6	5
44	The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD). Biology of Blood and Marrow Transplantation, 2019, 25, S26-S27.	2.0	4
45	Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study). Biology of Blood and Marrow Transplantation, 2020, 26, S180-S181.	2.0	4
46	Routine Prophylaxis of Pneumocystis Jirovecii Pneumonia in Recipients of Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, S116-S117.	2.0	3
47	Comparison of Gvhd Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality. Biology of Blood and Marrow Transplantation, 2019, 25, S53-S54.	2.0	3
48	Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.. Blood, 2008, 112, 2150-2150.	0.6	3
49	Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants.. Blood, 2008, 112, 2163-2163.	0.6	3
50	T/B and not T/B: High frequency of B-cell dyscrasias in T-LGL leukemia. Leukemia and Lymphoma, 2008, 49, 845-846.	0.6	2
51	A Phase I/II Clinical Trial of Type 1 Interferon for Reduction of Relapse after HCT in High Risk AML. Biology of Blood and Marrow Transplantation, 2019, 25, S12-S13.	2.0	2
52	Correlation of Radiographic Abnormalities on Computer Tomography (CT) with Broncho-Alveolar Lavage (BAL) Results. What are Our Radiologists Reading?. Biology of Blood and Marrow Transplantation, 2018, 24, S97-S98.	2.0	1
53	Impact of Broncho-Alveolar Lavage on the Diagnosis and Management of Pulmonary Complications Following Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S98.	2.0	1
54	The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.. Blood, 2005, 106, 1512-1512.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Blood</i> , 2015, 126, 1907-1907.	0.6	1
56	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509.	0.6	1
57	An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 463-463.	0.6	1
58	Pneumocystis Jirovecii Infection in Autologous Hematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2021, 138, 4898-4898.	0.6	1
59	A Combination of Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation From Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S138-S139.	2.0	0
60	Phase 2 Study of Allogeneic Hematopoietic Cell Transplant (HCT) Following Intermediate-Intensity Fludarabine and Busulfan x 4 (FluBu4) Conditioning for High-Risk or Advanced Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S238.	2.0	0
61	The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S204-S205.	2.0	0
62	Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis GVHD Prophylaxis Following Unrelated Donor Reduced Intensity Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S337.	2.0	0
63	Ultrasensitive Genomic Minimal Residual Disease Detection in Peripheral Blood after Allogeneic HSCT for MDS Is Associated with Increased Relapse Risk and Inferior Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S127-S128.	2.0	0
64	The utility of cognitive changes in identifying those with acute graft vs. host disease following allogeneic hematopoietic cell transplant. <i>Clinical Neuropsychologist</i> , 2020, 34, 969-980.	1.5	0
65	Is age a risk factor for cognitive changes following hematopoietic cell transplantation?. <i>Bone Marrow Transplantation</i> , 2021, 56, 567-569.	1.3	0
66	Long-Term Outcome of Cyclosporin A Therapy for T-Cell Large Granular Lymphocyte Leukemia.. <i>Blood</i> , 2007, 110, 2063-2063.	0.6	0
67	Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.. <i>Blood</i> , 2009, 114, 43-43.	0.6	0
68	Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease.. <i>Blood</i> , 2012, 120, 3119-3119.	0.6	0
69	Application Of BOS 0-Potential Criteria As a Predictor For Bronchiolitis Obliterans Syndrome In Allogeneic Stem Cell Transplant Patients. <i>Blood</i> , 2013, 122, 2060-2060.	0.6	0
70	Prognostic Value of TGF β 2 at Diagnosis of Chronic GvHD. <i>Blood</i> , 2014, 124, 5875-5875.	0.6	0
71	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016, 128, 510-510.	0.6	0